6XC Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Soleno Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$53.00 |
| 52 Week High | US$54.60 |
| 52 Week Low | US$32.90 |
| Beta | -1.44 |
| 11 Month Change | 12.91% |
| 3 Month Change | 28.89% |
| 1 Year Change | 154.81% |
| 33 Year Change | 530.95% |
| 5 Year Change | 129.44% |
| Change since IPO | 112.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6XC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 11.4% | -0.2% | 0.8% |
| 1Y | 154.8% | -16.9% | 9.1% |
Return vs Industry: 6XC exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 6XC exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 6XC volatility | |
|---|---|
| 6XC Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6XC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6XC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 33 | Anish Bhatnagar | soleno.life |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. Fundamentals Summary
| 6XC fundamental statistics | |
|---|---|
| Market cap | €2.37b |
| Earnings (TTM) | -€124.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.8x
P/E RatioIs 6XC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6XC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$131.16m |
| Earnings | -US$131.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6XC perform over the long term?
See historical performance and comparison